PHI BIOMED LEADING THE FUTURE OF SMART NANOMEDICINES

HOME > R&BD > 핵심기술

핵심기술

Transdermal Hyaluronate-Protein Conjugate
Contact Information
1 Company PHI BioMed, Korea
2 Manager Hye Ryoung Lee, MBA (aosora2001@yahoo.com)
3 Web Page http://www.phibiomed.co.kr
Researcher
4 Institute (Researcher) POSTECH (Prof. Sei Kwang Hahn)
5 Web Page http://bnl.postech.ac.kr
Technology
6 Title Transdermal Hyaluronate-Protein Conjugate
7 Composition Protein(Human grwth hormone and ovalbumin) conjugated with aldehyde-modified hyaluronate
8 Application
  • Cosmedicals for anti-aging treatment
  • Transdermal vaccine
  • Platform technology for transdermal protein delivery
9 Competitive Advantage
  • Highly efficient transdermal delivery without any additives
  • Simple conjugation method without denaturation of protein
  • High serum stability and biocompatibility
10 Stage of Development Preclinical development (Collaboration with Harvard Medical School)
11 Data Files
  • In Vitro biological activity
  • In Vivo imaging after transdermal application
  • PK in rats
  • In Vivo immunization data
12 Test Model Drug Human growth hormone, ovalbumin as a model vaccine
13 Representative Figure [Biomaterials, 33, 5947 (2012)]
Intellectual Property
14 Domestic Patents filed/granted KR10-2012-0012315
15 International(PCT) Patents filed/granted PCT/KR2013/001002
16 Ownership PHI BIOMED
17 Proposal Type Clinical Co-development/Licensing Out
TOP